Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack.

Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A (2016) 0.89

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A (2016) 0.86

The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. Front Immunol (2016) 0.75

Pediatric phase 1 trial and pharmacokinetic study of trebananib in relapsed solid tumors ADVL1115: A Children's Oncology Group phase 1 consortium report. Clin Cancer Res (2017) 0.75

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (1997) 15.48

Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell (1996) 9.10

Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med (2011) 8.93

A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63

Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature (1995) 8.12

Isolation of a tumor factor responsible for angiogenesis. J Exp Med (1971) 7.12

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 6.82

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther (2011) 3.53

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell (2004) 2.71

Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol (2003) 2.51

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A (2012) 2.50

Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst (1995) 2.47

Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Oncogene (2000) 2.32

Direct cell adhesion to the angiopoietins mediated by integrins. J Biol Chem (2001) 2.11

Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol (2009) 2.09

Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res (2005) 1.92

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol (2009) 1.87

Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res (2013) 1.73

Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol (2011) 1.72

Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem (1999) 1.60

Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res (2001) 1.53

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer (2011) 1.39

Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res (2007) 1.37

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer (2013) 1.35

Angiopoietin signaling in the vasculature. Exp Cell Res (2013) 1.35

Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer (2011) 1.34

Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther (2010) 1.27

A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res (2004) 1.15

Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression. PLoS One (2013) 1.14

Targeting the tumor microenvironment: focus on angiogenesis. J Oncol (2011) 1.09

Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin beta1-dependent adhesion to the extracellular matrix. Mol Cancer Res (2006) 1.08

Expressions and clinical significances of angiopoietin-1, -2 and Tie2 in human gastric cancer. Biochem Biophys Res Commun (2005) 1.07

Overcoming resistance to antiangiogenic therapies. Oncologist (2012) 1.05

Immunomodulatory effects of anti-angiogenic drugs. Leukemia (2011) 1.02

Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. Cancer Gene Ther (2004) 0.98

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation. Oncoimmunology (2013) 0.97

Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy. Cancer Res (2010) 0.97

Mechanistic effects of autophosphorylation on receptor tyrosine kinase catalysis: enzymatic characterization of Tie2 and phospho-Tie2. Biochemistry (2001) 0.95

Tie-2 and angiopoietin-1 expression in human thyroid tumors. Thyroid (2002) 0.93

Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics. Cancer J (2013) 0.90

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med (2014) 0.90

Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. Cancer Immunol Res (2014) 0.90

Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. Cancer Cell Microenviron (2015) 0.89

Angiogenic and growth factors in gastric cancer. J Surg Res (2014) 0.89

Angiogenic axis angiopoietin-1 and angiopoietin-2/Tie-2 in non-small cell lung cancer: a bronchoalveolar lavage and serum study. Adv Exp Med Biol (2013) 0.88

Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC Cancer (2014) 0.87

Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected]. PLoS One (2014) 0.83

A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma. Eur Respir J (2010) 0.82

A novel multiple tyrosine-kinase targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple solid tumors: cabozantinib. Anticancer Agents Med Chem (2015) 0.79

Diagnostic and prognostic potential of serum angiopoietin-2 expression in human breast cancer. Int J Clin Exp Pathol (2015) 0.78

Platelet-rich plasma extract prevents pulmonary edema through angiopoietin-Tie2 signaling. Am J Respir Cell Mol Biol (2015) 0.77

E2F1 renders prostate cancer cell resistant to ICAM-1 mediated antitumor immunity by NF-κB modulation. Mol Cancer (2014) 0.77

Clinical significance of serum angiopoietin-1 in malignant peritoneal mesothelioma. Cancer Invest (2013) 0.76